USPTO serial 79434997
AMCAP
Reviewed by CopyMark Law Group
Status 616
- Filing date
- Status date
- Registration date
- —
- Examiner
- GANESH, HARINI
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with AMCAP?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian A. Tollefson
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical drugs, namely, drug delivery agents in the final formulation, namely injectable solution formulated in lipid carriers, that provided release of the active ingredients for a wide variety of pharmaceutical products; medicines, namely, vaccines and medicines for treatment of cancer, rare metabolic diseases, autoimmune disease immunotherapy and regenerative medicines; chemical preparations mRNA formulated in chemical carrier, namely LNP, polymers, and non-organic nanoparticles, to prevent or treat infection, cancer, rare metabolic diseases, and autoimmune disease; biological preparations for medical purposes; chemico-pharmaceutical preparations mRNA formulated in chemical carrier, namely LNP, polymers, and non-organic nanoparticles, to prevent or treat infection, cancer, rare metabolic diseases, and autoimmune disease; biological reagents for medical purposes; vaccines; nucleic acid-based pharmaceutical and veterinary products; food and dietary substances for medical or veterinary use; therapeutic antibodies for human use for the treatment of vaccines and medicines for treatment of cancer, rare metabolic diseases, autoimmune disease immunotherapy and rare genetic diseases; dietary supplements and preparations; pharmaceutical preparations and natural medicines in the nature of medicinal herbal preparations for the treatment of vaccines and medicines for treatment of cancer, rare metabolic diseases, autoimmune disease immunotherapy and rare genetic diseases; nucleic acid-based preparations; cell-based preparations, namely, cell pharmaceutical preparations containing cultured cells for the treatment of inflammatory diseases, cancer and metabolic diseases; tissue-based preparations, namely, tissue preparations containing cells for the treatment of inflammatory diseases, cancer, regenerative medicines and metabolic diseases; biological preparations for the treatment of inflammatory diseases, cancer, regenerative medicines and metabolic diseases; biological preparations for medical and pharmaceutical use; diagnostic preparations; engineered biological tissues for medical purposes; sanitary preparations for medical purposes; advanced therapy medicinal products, namely, medicines for the treatment of inflammatory diseases, cancer, regenerative medicines and metabolic diseases; personalized medicine products, namely, pharmaceutical preparations being precision medicine for the treatment of inflammatory diseases, cancer, regenerative medicines and metabolic diseases; regenerative medicine products; somatic cell therapy products, namely, stem cells, blood cells, skin cells, pancreatic cells, endothelial cells, and nerve cells for medical use; gene therapy products, namely, genetically engineered tissues and/or cells for regenerative and therapeutics purposes; recombinant human protein and nucleic acid sequences being biochemical preparations for use in cell culturing, cell therapy and for medical use | ACTIVE | — |
| 042 | Research and development of vaccines and nucleic acid-based medicines; scientific and technological services, namely, scientific research, analysis, testing in the field of pharmaceuticals, cell and gene therapy, biology, vaccines; research services in the medical and pharmaceutical fields; development of pharmaceutical preparations and medicines; development of pharmaceutical reagents and medicines; providing information and data relating to medical and veterinary research and development; medical laboratories; design and development of hardware and software; research and development in the biochemical and nucleic acid fields; research and development services in the field of microorganisms and cells; research and development services in the field of diagnostic preparations; research and development in the pharmaceutical and biotechnological sector; research and development services for the pharmaceutical industry; scientific research in the biological field; research on medicines; research on reagents; medical research laboratory services; research services for the development of new pharmaceutical products and advanced therapies; development of biological drugs and advanced therapies; biological and chemical analysis in the medical and pharmaceutical fields | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 6, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 6, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 6, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 6, 2026 | PETG | PETITION TO REVIVE-GRANTED | — |
| Nov 6, 2026 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Aug 20, 2026 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 20, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 26, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 6, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 5, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 10, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 9, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 17, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 21, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 21, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 16, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |